Nasdaq:MEDP
Medpace Holdings, Inc.
A premier oncology-focused contract research organization driving clinical trial efficiency with over $2.5B in annual revenue.
Key Metrics
Investment Thesis
Bull Case
Investors should consider MEDP for its dominant market position in the high-growth oncology CRO niche and consistent revenue expansion evidenced by a 49% increase from 2022 to 2025. The company's ability to generate substantial free cash flow while returning over $900M in buybacks demonstrates a commitment to capital efficiency and shareholder value creation.
Bear Case
Potential buyers should be cautious regarding the company's elevated current liabilities of $1.34B relative to assets, which could constrain flexibility if project funding slows. The heavy dependence on oncology trials exposes MEDP to specific scientific failures or regulatory delays that could disproportionately impact its revenue stream compared to diversified peers.
About Medpace Holdings, Inc.
Medpace Holdings (MEDP) is a leading contract research organization specializing in oncology clinical trials across North America. The company operates primarily as a CRO provider, managing drug development programs for biopharmaceutical clients by handling patient recruitment and trial execution. With recent revenue growth reaching $2.53B in 2025, the firm serves global sponsors seeking accelerated pathways to market approval.
Analysis
Management Discussion
The company demonstrated robust financial performance with net profit climbing to $451.1M in 2025, up from $404.4M the prior year, reflecting strong operational leverage on its core oncology portfolio. Despite a significant cash outflow from financing activities of -$860.4M largely driven by share repurchases totaling $917.4M, operating cash flow remained healthy at $713.2M, supporting aggressive capital return to shareholders while maintaining a strong balance sheet.
Industry Overview
The contract research organization industry is expanding rapidly as biopharmaceutical companies outsource non-core activities to focus on drug discovery and commercialization. Success fees and milestone payments are becoming more prevalent, shifting revenue models toward performance-based compensation linked to successful clinical trial outcomes and regulatory approvals.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.46B | $1.89B | $2.11B | $2.53B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $1.46B | $1.89B | $2.11B | $2.53B |
| Operating Expenses | $1.18B | $1.55B | $1.66B | $2.00B |
| Operating Income | $278.7M | $336.8M | $446.9M | $534.9M |
| G&A | $131.4M | $161.4M | $180.2M | $197.6M |
| Stock-Based Comp | $21.4M | $20.5M | $25.5M | $34.8M |
| Depreciation | $19.0M | $24.1M | $27.8M | $27.2M |
| Amortization | $3.4M | $2.2M | $1.4M | $946.0K |
| Other OpEx | $1.05B | $1.39B | $1.48B | $1.80B |
| Non-Operating Income | $4.2M | $-1.1M | $29.1M | $7.4M |
| Pre-Tax Income | $282.9M | $335.7M | $475.9M | $542.4M |
| Income Tax | $37.5M | $52.9M | $71.5M | $91.3M |
| Continuing Ops | $245.4M | $282.8M | $404.4M | $451.1M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $245.4M | $282.8M | $404.4M | $451.1M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $245.4M | $282.8M | $404.4M | $451.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $334.0M | $593.8M | $1.03B | $989.6M |
| Cash & Equivalents | $28.3M | $245.4M | $669.4M | $497.0M |
| Prepaid Expenses | $52.3M | $50.0M | $63.4M | $90.5M |
| Other Current Assets | $253.4M | $298.4M | $296.4M | $402.1M |
| Long-Term Assets | $1.02B | $1.06B | $1.07B | $985.8M |
| PP&E (Net) | $109.8M | $120.6M | $123.6M | $131.1M |
| Intangibles | $38.0M | $35.8M | $34.4M | $33.4M |
| Goodwill | $662.4M | $662.4M | $662.4M | $662.4M |
| Operating Leases | $139.1M | $144.8M | $128.6M | $117.8M |
| Other LT Assets | $69.2M | $99.4M | $122.6M | $41.2M |
| Total Assets | $1.35B | $1.66B | $2.10B | $1.98B |
| Current Liabilities | $803.5M | $925.1M | $1.10B | $1.34B |
| Accounts Payable | $33.1M | $31.9M | $32.5M | $28.1M |
| Current Leases | $19.3M | $22.4M | $23.3M | $23.2M |
| Deferred Revenue | $462.7M | $559.9M | $710.6M | $854.4M |
| Other Current Liab | $78.3M | $18.1M | $30.3M | $29.6M |
| Long-Term Liabilities | $162.6M | $172.7M | $170.8M | $172.7M |
| LT Operating Leases | $138.9M | $142.1M | $126.2M | $113.6M |
| Other LT Liab | $23.8M | $30.6M | $44.5M | $59.0M |
| Total Liabilities | $966.1M | $1.10B | $1.28B | $1.52B |
| Shareholders' Equity | $386.4M | $559.0M | $825.5M | $459.1M |
| Retained Earnings | $-359.8M | $-221.6M | $8.2M | $-460.0M |
| AOCI | $-12.4M | $-10.1M | $-14.7M | $-4.9M |
| Treasury Stock | $12.5M | — | — | — |
| Total L&E | $1.35B | $1.66B | $2.10B | $1.98B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $245.4M | $282.8M | $404.4M | $451.1M |
| Non-Cash Adjustments | $-89.4M | $-65.7M | $75.1M | $-78.3M |
| Working Capital Changes | $232.0M | $216.3M | $129.3M | $340.4M |
| Cash from Operations | $388.1M | $433.4M | $608.8M | $713.2M |
| Capital Expenditures | $36.9M | $36.6M | $36.5M | $31.4M |
| Cash from Investing | $-38.7M | $-34.6M | $-28.3M | $-31.1M |
| Share Buybacks | $847.8M | $144.0M | $169.9M | $917.4M |
| Cash from Financing | $-775.8M | $-182.6M | $-154.0M | $-860.4M |
| FX Effect | $-6.6M | $1.1M | $-2.5M | $5.9M |
| Net Change in Cash | $-433.0M | $217.2M | $424.0M | $-172.4M |
| Beginning Cash | $461.3M | $28.3M | $245.4M | $669.4M |
| Ending Cash | $28.3M | $245.4M | $669.4M | $497.0M |
Frequently Asked Questions
How does Medpace Holdings, Inc. make money?
Oncology Clinical Trials (primary revenue driver), Global Trial Management Services, and Specialized Patient Recruitment solutions for biopharmaceutical sponsors.
What are the main risks for MEDP?
Heavy reliance on the oncology sector which faces regulatory headwinds and reimbursement pressures, potential loss of major sponsor contracts impacting recurring revenue, fluctuating success fees tied to clinical outcomes, and intense competition from larger diversified CRO giants.
What is MEDP's competitive advantage?
Deep specialization in rare and complex oncology trials, a proprietary patient recruitment network with high enrollment rates, and an agile operational model that reduces trial timelines compared to traditional CROs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.